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Over the last while, several investigators have explored the role of
bone marrow-derived mononuclear cells in promoting angiogenesis
or neovascularization in patients with critical limb ischemia (CLI)
who have no other treatment option. The JUVENTAS (reJUVenat-
ing ENdothelial progenitor cells via Transcutaneous intra-Arterial
Supplementation) trialists describe the background and rationale of
this randomized study. There are a number of questions that perme-
ate this and other similar studies.
Study subjects include patients with critical limb ischemia and
severe claudication who are not candidates for revascularization as
determined by a team of radiologists and surgeons. This is consis-
tent with other studies, but what does it mean? Revascularization
suitability is a criterion that is open to disagreement and variability.
It certainly adds a subjective component to patient selection and
can make it difficult to compare the results of different studies.
The study investigators’ decision to include severe claudicants
raises some issues. First of all, some would argue that claudicants
are more likely to be suitable for intervention and are less likely to
have no revascularization options than those with CLI. Secondly,
claudicants are less likely to undergo major amputation and, as thissize calculation, the more claudicants included, the higher the
chance of an underpowered study. According to the investigators,
only three claudicants have been included in the over 60 subjects
recruited to date, so this may not be a major issue.
Several practical questions remain as well, including mode of
delivery. Is the best method of delivery intra arterial, as in JUVEN-
TAS, or intramuscular, or a combination as used by other investi-
gators?1 Additionally, what is the best method of determining
neovascularization? Is it magnetic resonance angiography, as in
this study, or angiography, duplex ultrasound, and/or ankle bra-
chial indices, as used by others?
This is an important and exciting area of investigation involv-
ing patients who often have no alternative but major amputation.
Hopefully, this randomized trial will clarify some of the issues
regarding this form of therapy.
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